Buspirone
| Clinical data | |
|---|---|
| Pronunciation | /ˈbjuːspɪroʊn/ (BEW-spi-rohn) |
| Trade names | Buspar, others |
| Other names | MJ 9022-1[1] |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a688005 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 3.9%[6] |
| Protein binding | 86–95%[7] |
| Metabolism | Liver (via CYP3A4)[11][12] |
| Metabolites | 5-OH-Buspirone; 6-OH-Buspirone; 8-OH-Buspirone; 1-PP[8][9][10] |
| Elimination half-life | 2.5 hours[11] |
| Excretion | Urine: 29–63%[7] Feces: 18–38%[7] |
| Identifiers | |
IUPAC name
| |
| CAS Number |
|
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.048.232 |
| Chemical and physical data | |
| Formula | C21H31N5O2 |
| Molar mass | 385.512 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
| |
| (verify) | |
Buspirone is an anxiolytic medication primarily used for the treatment of generalized anxiety disorder. Unlike benzodiazepines, buspirone does not produce significant sedation, dependence, or withdrawal effects. Its principal mechanism of action involves partial agonism at postsynaptic serotonin 5-HT₁A receptors and full agonism at presynaptic 5-HT₁A autoreceptors, which initially reduces serotonergic neuron firing. Over time, autoreceptor desensitization occurs, leading to increased serotonin release and enhanced serotonergic tone, which may contribute to its clinical efficacy. Buspirone also has weak antagonistic effects at dopamine D2, D3, and D4 receptors and α1- and α2-adrenergic receptors.
Buspirone is approved for the management of generalized anxiety disorder. It is sometimes used off-label for other anxiety disorders, depression augmentation, and certain behavioral conditions. Buspirone is not effective as a sedative-hypnotic or muscle relaxant and does not have anticonvulsant properties.
Common side effects of buspirone include nausea, headaches, dizziness, and difficulty concentrating.[13][14] Serious side effects may include movement disorders, serotonin syndrome, and seizures.[14] Its use in pregnancy appears to be safe but has not been well studied, and use during breastfeeding has not been well studied either.[14][15]
Buspirone was developed in 1968 and approved for medical use in the United States in 1986.[13][16] It is available as a generic medication.[14] In 2023, it was the 40th most commonly prescribed medication in the United States, with more than 15 million prescriptions.[17][18]
- ^ Cite error: The named reference
Elks2014was invoked but never defined (see the help page). - ^ "TGA eBS - Product and Consumer Medicine Information Licence".
- ^ "Anksilon (Orion Pharma (AUS) Pty Limited)". Therapeutic Goods Administration (TGA). 19 February 2025. Retrieved 7 March 2025.
- ^ "Anksilon buspirone hydrochloride 5 mg tablet blister pack (422891)". Therapeutic Goods Administration (TGA). 17 January 2025. Retrieved 7 March 2025.
- ^ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
- ^ Loane C, Politis M (June 2012). "Buspirone: what is it all about?". Brain Research. 1461: 111–118. doi:10.1016/j.brainres.2012.04.032. PMID 22608068. S2CID 11734819.
- ^ a b c "buspirone (Rx) - BuSpar, Buspirex, more." Medscape Reference. WebMD. Retrieved 14 November 2013.
- ^ Cite error: The named reference
pmid3515929was invoked but never defined (see the help page). - ^ Cite error: The named reference
SchatzbergNemeroff2009was invoked but never defined (see the help page). - ^ Cite error: The named reference
pmid17494642was invoked but never defined (see the help page). - ^ a b Mahmood I, Sahajwalla C (April 1999). "Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug". Clinical Pharmacokinetics. 36 (4): 277–287. doi:10.2165/00003088-199936040-00003. PMID 10320950. S2CID 1102318.
- ^ Zhu M, Zhao W, Jimenez H, Zhang D, Yeola S, Dai R, et al. (April 2005). "Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes". Drug Metabolism and Disposition. 33 (4): 500–507. doi:10.1124/dmd.104.000836. PMID 15640381. S2CID 10142905.
- ^ a b "Buspirone Hydrochloride Monograph for Professionals". Drugs.com.
- ^ a b c d British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 338. ISBN 9780857113382.
- ^ "Buspirone Pregnancy and Breastfeeding Warnings". Drugs.com.
- ^ Wilson TK, Tripp J (January 2018). "Buspirone". StatPearls. PMID 30285372.
- ^ "Top 300 of 2023". ClinCalc. Archived from the original on 12 August 2025. Retrieved 12 August 2025.
- ^ "Buspirone Drug Usage Statistics, United States, 2013 - 2023". ClinCalc. Retrieved 18 August 2025.